Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
Active, not recruiting · Phase 2 · NCT06268886
Conditions: Alzheimer Disease, Early Onset
At a glance
- Research payments reported, 2025
- $9,871
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 310
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986446 (drug), Placebo (other)
- Dates
- Started 2024-03-20; completion 2028-04-17
- Results posted
- Not yet
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
From ClinicalTrials.gov, last updated 2026-11-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $9,871 in research payments for this study in 2025 (6 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Doris Chen Neurology · Sacramento, CA
- Eric J. Grigsby, M.D. Pain Medicine · Napa, CA
- Marc E. Agronin, M.D. Psychiatry · Miami, FL
- Kelley A. Wilson, M.D. Psychiatry · Tampa, FL
- Sara Dawit, MD Hospitalist · Roswell, GA
- William M. Redden, M.D. Psychiatry · Saint Louis, MO
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of California Davis Medical Center, CA $4,710
- Saint Louis University (slu) Care - Monteleone Hall $2,508
- Alzheimers Research and Treatment Center $1,531
- K2 Medical Research $443
- Miami Jewish Home & Hospital $415
- Napa Surgery Center $264
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.